Preclinical modeling of myelodysplastic syndromes

K. Rouault-Pierre; S. A. Mian; M. Goulard; A. Abarrategi; A. Di Tulio; A. E. Smith; A. Mohamedali; S. Best; A. M. Nloga; A. G. Kulasekararaj; L. Ades; C. Chomienne; P. Fenaux; C. Dosquet; G. J. Mufti; D. Bonnet

doi:10.1038/leu.2017.172

Preclinical modeling of myelodysplastic syndromes

K. Rouault-Pierre, S. A. Mian, M. Goulard, A. Abarrategi, A. Di Tulio, A. E. Smith, A. Mohamedali, S. Best, A. M. Nloga, A. G. Kulasekararaj, L. Ades, C. Chomienne, P. Fenaux, C. Dosquet, G. J. Mufti, D. Bonnet

Comprehensive Cancer Centre

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

183 Downloads (Pure)

Abstract

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.

Original language	English
Pages (from-to)	2702-2708
Number of pages	7
Journal	Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Volume	31
Issue number	12
Early online date	2 Jun 2017
DOIs	https://doi.org/10.1038/leu.2017.172
Publication status	Published - 1 Dec 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2017.172Licence: CC BY

Preclinical modeling ROUAULT PIERRE Accepted 23May2017 GOLD VoR CCBYFinal published version, 1.6 MBLicence: CC BY

Cite this

Rouault-Pierre, K., Mian, S. A., Goulard, M., Abarrategi, A., Di Tulio, A., Smith, A. E., Mohamedali, A., Best, S., Nloga, A. M., Kulasekararaj, A. G., Ades, L., Chomienne, C., Fenaux, P., Dosquet, C., Mufti, G. J., & Bonnet, D. (2017). Preclinical modeling of myelodysplastic syndromes. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 31(12), 2702-2708. https://doi.org/10.1038/leu.2017.172

@article{f1e91c5859964c83a19bbb1ef1df6b35,

title = "Preclinical modeling of myelodysplastic syndromes",

abstract = "Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.",

author = "K. Rouault-Pierre and Mian, {S. A.} and M. Goulard and A. Abarrategi and {Di Tulio}, A. and Smith, {A. E.} and A. Mohamedali and S. Best and Nloga, {A. M.} and Kulasekararaj, {A. G.} and L. Ades and C. Chomienne and P. Fenaux and C. Dosquet and Mufti, {G. J.} and D. Bonnet",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/leu.2017.172",

language = "English",

volume = "31",

pages = "2702--2708",

journal = "Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K",

issn = "1476-5551",

publisher = "Springer Nature [academic journals on nature.com]",

number = "12",

}

Rouault-Pierre, K, Mian, SA, Goulard, M, Abarrategi, A, Di Tulio, A, Smith, AE , Mohamedali, A , Best, S, Nloga, AM, Kulasekararaj, AG, Ades, L, Chomienne, C, Fenaux, P, Dosquet, C, Mufti, GJ & Bonnet, D 2017, 'Preclinical modeling of myelodysplastic syndromes', Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, vol. 31, no. 12, pp. 2702-2708. https://doi.org/10.1038/leu.2017.172

TY - JOUR

T1 - Preclinical modeling of myelodysplastic syndromes

AU - Rouault-Pierre, K.

AU - Mian, S. A.

AU - Goulard, M.

AU - Abarrategi, A.

AU - Di Tulio, A.

AU - Smith, A. E.

AU - Mohamedali, A.

AU - Best, S.

AU - Nloga, A. M.

AU - Kulasekararaj, A. G.

AU - Ades, L.

AU - Chomienne, C.

AU - Fenaux, P.

AU - Dosquet, C.

AU - Mufti, G. J.

AU - Bonnet, D.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.

AB - Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematological clonal disorders. Here, we have tested the bone marrow (BM) cells from 38 MDS patients covering all risk groups in two immunodeficient mouse models: NSG and NSG-S. Our data show comparable level of engraftment in both models. The level of engraftment was patient specific with no correlation to any specific MDS risk group. Furthermore, the co-injection of mesenchymal stromal cells (MSCs) did not improve the level of engraftment. Finally, we have developed an in vitro two-dimensional co-culture system as an alternative tool to in vivo. Using our in vitro system, we have been able to co-culture CD34+ cells from MDS patient BM on auto- and/or allogeneic MSCs over 4 weeks with a fold expansion of up to 600 times. More importantly, these expanded cells conserved their MDS clonal architecture as well as genomic integrity.

UR - http://www.scopus.com/inward/record.url?scp=85038255780&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.172

DO - 10.1038/leu.2017.172

M3 - Article

C2 - 28663577

AN - SCOPUS:85038255780

SN - 1476-5551

VL - 31

SP - 2702

EP - 2708

JO - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

JF - Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K

IS - 12

ER -

Preclinical modeling of myelodysplastic syndromes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Preclinical modeling of myelodysplastic syndromes

Cite this